Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions

Pharmacological Research

Volumn 65, Issue 5, 2012, Pages 553-563

  Sasso, Oscar ^a   Bertorelli, Rosalia ^a   Bandiera, Tiziano ^a   Scarpelli, Rita ^a   Colombano, Giampiero ^a   Armirotti, Andrea ^a   Moreno Sanz, Guillermo ^a   Reggiani, Angelo ^a   Piomelli, Daniele ^a,b  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anandamide; Cannabinoid receptors; Gastric lesions; Inflammation; Neuropathic pain

Indexed keywords

[3 (3 CARBAMOYLPHENYL) 4 HYDROXY PHENYL] N CYCLOHEXYLCARBAMATE; CARRAGEENAN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXAMETHASONE; FATTY ACID AMIDASE INHIBITOR; FREUND ADJUVANT; GABAPENTIN; INDOMETACIN; N PYRIDAZIN 3 YL 4 [[3 [[5 (TRIFLUOROMETHYL) 2 PYRIDYL]OXY]PHENYL]METHYLENE]PIPERIDINE 1 CARBOXAMIDE; UNCLASSIFIED DRUG; URB 937;

ALLODYNIA; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; HYPERALGESIA; ISOBOLOGRAPHIC ANALYSIS; MALE; MECHANICAL HYPERALGESIA; MOUSE; NERVE LIGATION; NONHUMAN; PAIN; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; SCIATIC NERVE; STOMACH LESION; THERMAL HYPERALGESIA; ULCEROGENESIS;

AMIDOHYDROLASES; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BENZAMIDES; CANNABINOIDS; CARBAMATES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HYPERALGESIA; INDOMETHACIN; MALE; MICE; PAIN; PYRIDAZINES; SCIATIC NERVE; STOMACH ULCER; UREA;

EID: 84859793552     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.02.012     Document Type: Article

References (42)

1. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005;74:411-32. (Pubitemid 40995513)
2. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9. (Pubitemid 23026736)
3. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003;4:873-84. (Pubitemid 37351427)
4. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003;425:90-3. (Pubitemid 37101723)
5. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005;67:15-9. (Pubitemid 40069962)
6. Lambert DM, Muccioli GG. Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players. Curr Opin Clin Nutr Metab Care 2007;10:735-44. (Pubitemid 350293775)
7. Hansen HS. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol 2010;224:48-55.
8. Seierstad M, Breitenbucher JG. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem 2008;51:7327-43.
9. Kathuria S, Gaetani S, Fegley D, Valĩno F, Duranti A, Tontini A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003;9:76-81. (Pubitemid 36098263)
10. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, et al. Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 2004;47:4998-5008. (Pubitemid 39314898)
11. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 2006;12:21-38. (Pubitemid 44133578)
12. Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, et al. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective FAAH inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther 2011;338:114-24.
13. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005;102:18620-5. (Pubitemid 43011275)
14. Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, et al. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 2007;322:236-42. (Pubitemid 46956375)
15. Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 2010;13:1265-70.
16. Moreno-Sanz G, Barrera B, Guijarro A, d'Elia I, Otero JA, Alvarez AI, et al. ABCG2 (BCRP) restricts access of FAAH inhibitor URB937 to the central nervous system. Pharmacol Res 2011;64:359-63.
17. Qin CX, Chen X, Hughes RA, Williams SJ, Woodman OL. Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity. J Med Chem 2008;51:1874-84. (Pubitemid 351438869)
18. Reed MJ, Potter BVL US2006/0241173.
19. Fay LK, Johnson DS, Kesten SR, Lazerwith SE, Morris MA, Stiff CM, et al. US2008/0261941.
20. Johnson DS, Stiff C, Lazerwith SE, Kesten SR, Fay LK, Morris M, et al. Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor. ACS Med Chem Lett 2011;2:91-6.
21. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87-107.
22. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32:77-88.
23. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995;3:1531-7.
24. Jain NK, Kulkarni SK, Singh A. Modulation of NSAID-induced antinociceptive and anti-inflammatory effects by alpha2-adrenoceptor agonists with gastroprotective effects. Life Sci 2002;70:2857-69. (Pubitemid 34442518)
25. Tallarida R. Drug synergism and dose-effect data analysis. Boca Raton, FL: Chapman & Hall/CRC Press; 2000.
26. Naidu PS, Booker L, Cravatt BF, Lichtman AH. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 2009;329:48-56.
27. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010;24:121-32.
28. Stein C, Zöllner C. Opioids and sensory nerves. Handb Exp Pharmacol 2009;194:495-518.
29. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-81. (Pubitemid 28335039)
30. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998;75:111-9. (Pubitemid 28254862)
31. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 2009;8:403-21.
32. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007;10:870-9. (Pubitemid 47013432)
33. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2008;10:R43.
34. Kaufmann I, Hauer D, Huge V, Vogeser M, Campolongo P, Chouker A, et al. Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report. Eur Surg Res 2009;43:325-9.
35. Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet 2006;120:581-8. (Pubitemid 44669791)
36. Proudnikov D, Kroslak T, Sipe JC, Randesi M, Li D, Hamon S, et al. Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1. Pharmacogenomics J 2010;10:232-42.
37. Pernía-Andrade AJ, Kato A, Witschi R, Nyilas R, Katona I, Freund TF, et al. Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 2009;325:760-4.
38. Boyce JA. Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev 2007;217:168-85. (Pubitemid 46718145)
39. Gühring H, Hamza M, Sergejeva M, Ates M, Kotalla CE, Ledent C, et al. A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol 2002;454:153-63. (Pubitemid 35287474)
40. Telleria-Diaz A, Schmidt M, Kreusch S, Neubert AK, Schache F, Vazquez E, et al. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: involvement of prostaglandins and endocannabinoids. Pain 2010;148:26-35.
41. Staniaszek LE, Norris LM, Kendall DA, Barrett DA, Chapman V. Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids. Br J Pharmacol 2010;160:669-76.
42. Warzecha Z, Dembinski A, Ceranowicz P, Dembinski M, Cieszkowski J, Kownacki P, et al. Role of sensory nerves in gastroprotective effect of anandamide in rats. J Physiol Pharmacol 2011;62:207-17.